Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co prepares to file first-in-class insomnia drug for US approval

Will submit orexin receptor antagonist suvorexant to the FDA later this year

Merck & Co is planning to submit its potential first-in-class insomnia treatment suvorexant for US approval later this year.

If approved suvorexant would enter a US sleep drug market worth an estimated $2bn in 2010, with sales led by Sanofi's Ambien CR and Sunovion's Lunestra.

Two phase III trials of the orexin receptor antagonist suvorexant have been completed and the company said they show positive results.

"Suvorexant selectively targets an important pathway involved in helping to promote sleep and, if approved, will be a new, first-in-class treatment for patients with insomnia," said Peter Kim, president, Merck Research Laboratories.

"We are enthusiastic about the potential of this investigational medicine, and look forward to sharing the results from these studies with the medical community."

The primary endpoint for the trials was change from baseline in subjective total sleep time and time to sleep onset, wake time after persistent sleep onset, and latency to onset of persistent sleep at one and three months.

Merck plans to present data from the studies at medical meetings later this year.

Suvorexant is one of five major US filings the company hopes to make in 2012 and 2013, along with neuromuscular reversal agent Bridion (sugammadex), HPV vaccine V503, osteoporosis treatment odanacatib and atherosclerosis medicine Tredaptive ER.

7th February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics